

115TH CONGRESS
2D SESSION

H. R. 6717

To amend the Federal Food, Drug, and Cosmetic Act to require that the label of drugs with an increased risk of suicide or depression present such increased risk prominently, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

SEPTEMBER 6, 2018

Mr. RUSH introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend the Federal Food, Drug, and Cosmetic Act to require that the label of drugs with an increased risk of suicide or depression present such increased risk prominently, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Depression Side Effect
5 Labeling Awareness Act of 2018”.

1 **SEC. 2. PROMINENT DRUG LABELING FOR INCREASED RISK**
2 **OF SUICIDE OR DEPRESSION.**

3 (a) IN GENERAL.—Section 502 of the Federal Food,
4 Drug, and Cosmetic Act (21 U.S.C. 352) is amended by
5 adding at the end the following:

6 “(ee) If the warnings and precautions in the drug’s
7 label include an increased risk of suicide or depression,
8 unless such increased risk is presented prominently.”.

9 (b) REGULATIONS.—Not later than 1 year after the
10 date of enactment of this Act, the Secretary of Health and
11 Human Services, acting through the Commissioner of
12 Food and Drugs, shall promulgate final regulations to
13 carry out section 502(ee) of the Federal Food, Drug, and
14 Cosmetic Act, as added by subsection (a). Before promul-
15 gating such regulations, the Secretary shall consult with
16 stakeholders, including manufacturers of drugs.

17 (c) DELAYED APPLICABILITY.—Such section 502(ee)
18 shall not apply until the Secretary of Health and Human
19 Services has issued a final regulation under subsection (b).

